vs

Side-by-side financial comparison of BridgeBio Pharma, Inc. (BBIO) and Fiverr International Ltd. (FVRR). Click either name above to swap in a different company.

Fiverr International Ltd. is the larger business by last-quarter revenue ($287.8M vs $154.2M, roughly 1.9× BridgeBio Pharma, Inc.). Fiverr International Ltd. runs the higher net margin — 1.9% vs -126.2%, a 128.1% gap on every dollar of revenue. Fiverr International Ltd. produced more free cash flow last quarter ($52.1M vs $-56.5M).

Brent Saunders is an American biopharma executive and entrepreneur who is the chairman and CEO of the health company Bausch & Lomb. He helped lead various mergers and acquisitions, including the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He founded the special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthet...

Fiverr International Ltd. operates a global online freelance services marketplace connecting businesses and independent creators across over 160 countries. It offers services covering digital marketing, graphic design, programming, writing, video editing, and other professional fields, catering to SMEs, startups, and enterprise clients needing flexible on-demand talent solutions.

BBIO vs FVRR — Head-to-Head

Bigger by revenue
FVRR
FVRR
1.9× larger
FVRR
$287.8M
$154.2M
BBIO
Higher net margin
FVRR
FVRR
128.1% more per $
FVRR
1.9%
-126.2%
BBIO
More free cash flow
FVRR
FVRR
$108.5M more FCF
FVRR
$52.1M
$-56.5M
BBIO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
BBIO
BBIO
FVRR
FVRR
Revenue
$154.2M
$287.8M
Net Profit
$-194.6M
$5.4M
Gross Margin
94.7%
82.5%
Operating Margin
-90.5%
-3.5%
Net Margin
-126.2%
1.9%
Revenue YoY
2521.2%
Net Profit YoY
27.2%
EPS (diluted)
$-1.00

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BBIO
BBIO
FVRR
FVRR
Q4 25
$154.2M
Q3 25
$120.7M
$287.8M
Q2 25
$110.6M
$188.2M
Q1 25
$116.6M
$93.5M
Q3 24
$269.9M
Q2 24
$177.3M
Q1 24
$211.1M
$88.0M
Q3 23
$254.2M
Net Profit
BBIO
BBIO
FVRR
FVRR
Q4 25
$-194.6M
Q3 25
$-184.9M
$5.4M
Q2 25
$-183.8M
$4.1M
Q1 25
$-169.6M
$788.0K
Q3 24
$-1.0M
Q2 24
$-4.0M
Q1 24
$-36.2M
$-4.3M
Q3 23
$-70.2M
Gross Margin
BBIO
BBIO
FVRR
FVRR
Q4 25
94.7%
Q3 25
94.6%
82.5%
Q2 25
96.7%
83.3%
Q1 25
97.7%
83.5%
Q3 24
82.8%
Q2 24
82.4%
Q1 24
99.7%
82.2%
Q3 23
80.3%
Operating Margin
BBIO
BBIO
FVRR
FVRR
Q4 25
-90.5%
Q3 25
-120.3%
-3.5%
Q2 25
-121.4%
-3.4%
Q1 25
-89.5%
-4.4%
Q3 24
-5.0%
Q2 24
-6.3%
Q1 24
0.2%
-8.1%
Q3 23
-28.4%
Net Margin
BBIO
BBIO
FVRR
FVRR
Q4 25
-126.2%
Q3 25
-153.2%
1.9%
Q2 25
-166.2%
2.2%
Q1 25
-145.4%
0.8%
Q3 24
-0.4%
Q2 24
-2.3%
Q1 24
-17.1%
-4.9%
Q3 23
-27.6%
EPS (diluted)
BBIO
BBIO
FVRR
FVRR
Q4 25
$-1.00
Q3 25
$-0.95
Q2 25
$-0.95
Q1 25
$-0.88
Q3 24
Q2 24
Q1 24
$-0.20
Q3 23

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BBIO
BBIO
FVRR
FVRR
Cash + ST InvestmentsLiquidity on hand
$570.1M
$133.5M
Total DebtLower is stronger
$2.0B
Stockholders' EquityBook value
$-2.1B
$362.6M
Total Assets
$936.0M
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BBIO
BBIO
FVRR
FVRR
Q4 25
$570.1M
Q3 25
$643.0M
$133.5M
Q2 25
$756.9M
$578.4M
Q1 25
$540.6M
$133.5M
Q3 24
$183.7M
Q2 24
$183.7M
Q1 24
$519.7M
$183.7M
Q3 23
$86.8M
Total Debt
BBIO
BBIO
FVRR
FVRR
Q4 25
$2.0B
Q3 25
$2.0B
Q2 25
Q1 25
Q3 24
Q2 24
Q1 24
Q3 23
Stockholders' Equity
BBIO
BBIO
FVRR
FVRR
Q4 25
$-2.1B
Q3 25
$-1.9B
$362.6M
Q2 25
$-1.8B
$404.9M
Q1 25
$-1.6B
$362.6M
Q3 24
$355.8M
Q2 24
$355.8M
Q1 24
$-1.0B
$355.8M
Q3 23
$265.7M
Total Assets
BBIO
BBIO
FVRR
FVRR
Q4 25
$936.0M
Q3 25
$998.3M
$1.1B
Q2 25
$1.1B
$1.1B
Q1 25
$881.6M
$1.1B
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$849.3M
$1.0B
Q3 23
$923.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BBIO
BBIO
FVRR
FVRR
Operating Cash FlowLast quarter
$-56.4M
$53.0M
Free Cash FlowOCF − Capex
$-56.5M
$52.1M
FCF MarginFCF / Revenue
-36.6%
18.1%
Capex IntensityCapex / Revenue
0.0%
0.3%
Cash ConversionOCF / Net Profit
9.81×
TTM Free Cash FlowTrailing 4 quarters
$124.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BBIO
BBIO
FVRR
FVRR
Q4 25
$-56.4M
Q3 25
$-109.6M
$53.0M
Q2 25
$-80.7M
$42.2M
Q1 25
$-199.2M
$21.2M
Q3 24
$10.9M
Q2 24
$32.2M
Q1 24
$-219.5M
$21.2M
Q3 23
$20.5M
Free Cash Flow
BBIO
BBIO
FVRR
FVRR
Q4 25
$-56.5M
Q3 25
$-110.0M
$52.1M
Q2 25
$-81.3M
$41.5M
Q1 25
$20.8M
Q3 24
$10.6M
Q2 24
$31.5M
Q1 24
$-220.2M
$20.8M
Q3 23
$19.4M
FCF Margin
BBIO
BBIO
FVRR
FVRR
Q4 25
-36.6%
Q3 25
-91.2%
18.1%
Q2 25
-73.5%
22.0%
Q1 25
22.3%
Q3 24
3.9%
Q2 24
17.8%
Q1 24
-104.3%
23.7%
Q3 23
7.6%
Capex Intensity
BBIO
BBIO
FVRR
FVRR
Q4 25
0.0%
Q3 25
0.4%
0.3%
Q2 25
0.5%
0.4%
Q1 25
0.0%
0.4%
Q3 24
0.1%
Q2 24
0.4%
Q1 24
0.3%
0.4%
Q3 23
0.4%
Cash Conversion
BBIO
BBIO
FVRR
FVRR
Q4 25
Q3 25
9.81×
Q2 25
10.40×
Q1 25
26.90×
Q3 24
Q2 24
Q1 24
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons